Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

被引：18

作者：

Templeton, I. E. ^{[1
]}

Chen, Y. ^{[1
]}

Mao, J. ^{[1
]}

Lin, J. ^{[2
]}

Yu, H. ^{[3
]}

Peters, S. ^{[4
]}

Shebley, M. ^{[5
]}

Varma, M. V. ^{[2
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Pfizer Inc, Groton, CT 06340 USA

[3] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA

[4] AstraZeneca, Molndal, Sweden

[5] AbbVie Inc, N Chicago, IL USA

来源：

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2016年 / 5卷 / 10期

关键词：

D O I：

10.1002/psp4.12110

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug-drug interactions using physiologically based pharmacokinetic (PBPK) modeling. Three drugs with major circulating inhibitory metabolites (amiodarone, gemfibrozil, and sertraline) were systematically evaluated in addition to the literature review of recent examples. The application of PBPK modeling in drug interactions by inhibitory parent-metabolite pairs is described and guidance on strategic application is provided.

引用

页码：505 / 515

页数：11

共 50 条

[1] Prediction of Pharmacokinetic Drug-Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
Bu, Fengjiao
Cho, Yong-Soon
He, Qingfeng
Wang, Xiaowen
Howlader, Saurav
Kim, Dong-Hyun
Zhu, Mingshe
Shin, Jae Gook
Xiang, Xiaoqiang
DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4585 - 4600
[2] Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions
de Kanter, Ruben
Sidharta, Patricia N.
Delahaye, Stphane
Gnerre, Carmela
Segrestaa, Jerome
Buchmann, Stephan
Kohl, Christopher
Treiber, Alexander
CLINICAL PHARMACOKINETICS, 2016, 55 (03) : 369 - 380
[3] Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone
Chen, Yuan
Mao, Jialin
Hop, Cornelis E. C. A.
DRUG METABOLISM AND DISPOSITION, 2015, 43 (02) : 182 - 189
[4] Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites
Zhang, Tao
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 77 : 216 - 229
[5] Physiologically Based Pharmacokinetic Modeling of Rosuvastatin and Prediction of Transporter-Mediated Drug-Drug Interactions Involving Gemfibrozil
Macwan, J. S.
Lukacova, V.
Fraczkiewicz, G.
Bolger, M. B.
Akhlaghi, F.
Woltosz, W. S.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S39 - S39
[6] PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF ELAGOLIX FOR PREDICTION OF DRUG-DRUG INTERACTIONS (DDIS)
Chiney, M. S.
Polepally, A. R.
Nader, A. M.
Dufek, M. B.
Klein, C. E.
Ng, J. W.
Shebley, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S59 - S59
[7] Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes
Marzolini, Catia
Rajoli, Rajith
Battegay, Manuel
Elzi, Luigia
Back, David
Siccardi, Marco
CLINICAL PHARMACOKINETICS, 2017, 56 (04) : 409 - 420
[8] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
Ruijuan Xu
Weihong Ge
Qing Jiang
European Journal of Clinical Pharmacology, 2018, 74 : 755 - 765
[9] Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban
Xu, Ruijuan
Ge, Weihong
Jiang, Qing
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (06) : 755 - 765
[10] Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions
Baneyx, Guillaume
Fukushima, Yumi
Parrott, Neil
FUTURE MEDICINAL CHEMISTRY, 2012, 4 (05) : 681 - 693

← 1 2 3 4 5 →